Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

67.19 -1.61 (-2.34%)

Streaming Delayed Price Updated: 2:36 PM EST, Feb 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	258,561
Open	68.85
Bid (Size)	67.07 (100)
Ask (Size)	67.31 (300)
Prev. Close	68.80
Today's Range	66.12 - 69.73
52wk Range	47.86 - 94.07
Shares Outstanding	48,358,981
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

Today 10:26 EST

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder

February 04, 2026

From Arcellx, Inc.

Via Business Wire

Performance

YTD	+6.1%	+6.1%
1 Month	+3.6%	+3.6%
3 Month	-21.6%	-21.6%
6 Month	-2.8%	-2.8%
1 Year	+0.3%	+0.3%

More News

Arcellx Director Sells 6,000 Shares for $450,000 ↗

January 31, 2026

Via The Motley Fool

4 Analysts Assess Arcellx: What You Need To Know ↗

July 31, 2025

Via Benzinga

The Small-Cap M&A Boom of 2026: How $440 Billion in Dry Powder and Rate Cuts Are Remaking the Market

January 27, 2026

Via MarketMinute

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

January 21, 2026

From Arcellx, Inc.

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

December 06, 2025

From Arcellx, Inc.

Via Business Wire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

November 18, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Third Quarter 2025 Financial Results

November 05, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

November 03, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

September 03, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx (ACLX) Q2 Revenue Drops 72% ↗

August 07, 2025

Via The Motley Fool

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

August 07, 2025

From Arcellx, Inc.

Via Business Wire

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Via Investor's Business Daily

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025

From Arcellx, Inc.

Via Business Wire

Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗

May 21, 2025

Via Benzinga

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 14, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 08, 2025

From Arcellx, Inc.

Via Business Wire

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗

April 02, 2025

Via Benzinga

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

March 20, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

February 27, 2025

From Arcellx, Inc.

Via Business Wire

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

February 26, 2025

From Arcellx, Inc.

Via Business Wire

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗

February 12, 2025

Via Benzinga

Frequently Asked Questions

Is Arcellx, Inc. - Common Stock publicly traded?

Yes, Arcellx, Inc. - Common Stock is publicly traded.

What exchange does Arcellx, Inc. - Common Stock trade on?

Arcellx, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcellx, Inc. - Common Stock?

The ticker symbol for Arcellx, Inc. - Common Stock is ACLX on the Nasdaq Stock Market

What is the current price of Arcellx, Inc. - Common Stock?

The current price of Arcellx, Inc. - Common Stock is 67.19

When was Arcellx, Inc. - Common Stock last traded?

The last trade of Arcellx, Inc. - Common Stock was at 02/10/26 02:36 PM ET

What is the market capitalization of Arcellx, Inc. - Common Stock?

The market capitalization of Arcellx, Inc. - Common Stock is 3.25B

How many shares of Arcellx, Inc. - Common Stock are outstanding?

Arcellx, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.